Recent Long COVID research centers on identifying distinct disease biomarkers, characterizing brain dopamine dysfunction, and testing repurposed medications to alleviate symptoms. While a standardized cure remains elusive, significant advancements in understanding the condition’s biology are yielding promising new treatment strategies. [1, 2, 3, 4, 5]
Key Scientific and Clinical Advancements
Dopamine System Impairment: Brain imaging studies from the Centre for Addiction and Mental Health (CAMH) provide the strongest evidence yet that Long COVID is associated with measurable injury to dopamine-releasing neurons in the brain. This dopamine dysfunction explains symptoms like severe lack of motivation, cognitive fog, and movement issues, and points directly to treatments that enhance dopamine signaling. [1,2]
Chronic Inflammation: Harvard and Beth Israel Deaconess Medical Center researchers utilizing “multi-omic” techniques found evidence that Long COVID is driven by persistent activation of chronic inflammatory pathways and cellular metabolism disruptions. This shift away from just looking for hidden viruses indicates that targeting chronic inflammation directly could result in viable therapies. [1]
Symptom Trajectories: NIH-funded RECOVER studies tracked thousands of patients and identified eight distinct Long COVID trajectories (e.g., gradually improving, persistently severe, or intermittently severe). This helps clinicians better manage patient care and informs the biological research of the disease. [1]
Therapeutic Trials and Treatments
Modest Relief from Fatigue: A large-scale clinical trial published in The Lancet Infectious Diseases showed that inexpensive, widely available drugs-including colchicine (an antiinflammatory gout medication) and a combination of antihistamines (loratadine and famotidine)—offered modest short-term relief from Long COVID-related fatigue. [1]
Ongoing Clinical Trials: The second phase of the NIH’s RECOVER Treating Long COVID (RECOVER-TLC) initiative is actively running trials for repurposed drugs and interventions, evaluating therapies like low-dose naltrexone, baricitinib, and GLP-1 receptor agonists. [1]
To track the progress of ongoing trials, contribute to observational studies, or find resources for managing the condition, visit the RECOVER COVID Initiative. For a deeper look at the specific mechanisms and future clinical directions, read the
Break in the case for long COVID investigators - Harvard Gazette https://news.harvard.edu/gazette/story/2025/12/break-in-the-case-for-long-covidinvestigators
Study Reveals Insights into Long COVID Trajectories in Adults | Mass General Brigham https://www.massgeneralbrigham.org/en/about/newsroom/press-releases/insights-into-long-covid-trajectories-in-adults
Long COVID: current research and future directions : Infectious Diseases & Immunity https://www.ovid.com/jnls/idi/fulltext/10.1097/id9.0000000000000158~long-covid-current-research-and-future-directions
Current status and future perspectives on the mechanistic and pathophysiological understanding of long COVID | Communications Medicine https://www.nature.com/articles/s43856-025-01300-z
Brain Scans Reveal Dopamine Damage in Long COVID, Pointing to New Treatments | Inside Precision Medicine
https://www.insideprecisionmedicine.com/topics/coronavirus/brain-scans-reveal-dopamine-damage-in-long-covid-pointing-to-new-treatments
https://www.cidrap.umn.edu/covid-19/2-common-drugs-may-offer-short-term-improvements-long-covid-related-fatigue